Advanced

Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease.

Hesselstrand, Roger LU ; Andréasson, Kristofer LU ; Wuttge, Dirk LU ; Bozovic, Gracijela LU ; Scheja, Agneta LU and Saxne, Tore LU (2012) In Rheumatology (Oxford, England) 51(5). p.915-920
Abstract
Objectives. COMP is a regulator of assembly and maintenance of the fibrillar collagen I and II networks. Serum COMP reflects skin fibrosis in SSc. The purpose of this study was to examine whether serum COMP reflects fibrotic lung involvement in SSc patients and to study if serum COMP predicts mortality.Methods. Three overlapping cohorts of 244 SSc patients were studied. Two hundred and eighteen patients were included to study survival, 80 patients to study longitudinal changes of pulmonary function tests and 64 to study pulmonary involvement assessed by high-resolution CT (HRCT). Serum COMP was measured by ELISA. Skin involvement was assessed with the modified Rodnan skin score (mRSS). Data about survival were obtained from the central... (More)
Objectives. COMP is a regulator of assembly and maintenance of the fibrillar collagen I and II networks. Serum COMP reflects skin fibrosis in SSc. The purpose of this study was to examine whether serum COMP reflects fibrotic lung involvement in SSc patients and to study if serum COMP predicts mortality.Methods. Three overlapping cohorts of 244 SSc patients were studied. Two hundred and eighteen patients were included to study survival, 80 patients to study longitudinal changes of pulmonary function tests and 64 to study pulmonary involvement assessed by high-resolution CT (HRCT). Serum COMP was measured by ELISA. Skin involvement was assessed with the modified Rodnan skin score (mRSS). Data about survival were obtained from the central population registry.Results. Serum COMP measured within 5 years after the first non-Raynaud's manifestation was a predictor of death, and crude mortality increased by 6% for each COMP unit elevation. Serum COMP levels >15 U/l were associated with a 3.13-fold (95% CI 1.73, 5.64; P < 0.001) increased risk of death. During the first year of follow-up serum COMP and vital capacity (VC) changed inversely (r(s) = -0.32; P = 0.005), but there were no correlations between baseline serum COMP and concurrent findings by spirometry or HRCT.Conclusion. Serum COMP early in disease is a predictor of mortality in SSc patients. Serum COMP changes in parallel with lung fibrosis as measured by VC, but the release from fibrotic skin possibly obscures the influx from the lungs and therefore serum COMP seems to have little utility as a marker of lung fibrosis. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Rheumatology (Oxford, England)
volume
51
issue
5
pages
915 - 920
publisher
Oxford University Press
external identifiers
  • wos:000303159800023
  • pmid:22253028
  • scopus:84860238937
ISSN
1462-0332
DOI
10.1093/rheumatology/ker442
language
English
LU publication?
yes
id
7405bfec-3ecb-4348-8a34-ddda8121e40c (old id 2336257)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22253028?dopt=Abstract
date added to LUP
2012-02-01 21:51:30
date last changed
2017-05-28 04:38:38
@article{7405bfec-3ecb-4348-8a34-ddda8121e40c,
  abstract     = {Objectives. COMP is a regulator of assembly and maintenance of the fibrillar collagen I and II networks. Serum COMP reflects skin fibrosis in SSc. The purpose of this study was to examine whether serum COMP reflects fibrotic lung involvement in SSc patients and to study if serum COMP predicts mortality.Methods. Three overlapping cohorts of 244 SSc patients were studied. Two hundred and eighteen patients were included to study survival, 80 patients to study longitudinal changes of pulmonary function tests and 64 to study pulmonary involvement assessed by high-resolution CT (HRCT). Serum COMP was measured by ELISA. Skin involvement was assessed with the modified Rodnan skin score (mRSS). Data about survival were obtained from the central population registry.Results. Serum COMP measured within 5 years after the first non-Raynaud's manifestation was a predictor of death, and crude mortality increased by 6% for each COMP unit elevation. Serum COMP levels &gt;15 U/l were associated with a 3.13-fold (95% CI 1.73, 5.64; P &lt; 0.001) increased risk of death. During the first year of follow-up serum COMP and vital capacity (VC) changed inversely (r(s) = -0.32; P = 0.005), but there were no correlations between baseline serum COMP and concurrent findings by spirometry or HRCT.Conclusion. Serum COMP early in disease is a predictor of mortality in SSc patients. Serum COMP changes in parallel with lung fibrosis as measured by VC, but the release from fibrotic skin possibly obscures the influx from the lungs and therefore serum COMP seems to have little utility as a marker of lung fibrosis.},
  author       = {Hesselstrand, Roger and Andréasson, Kristofer and Wuttge, Dirk and Bozovic, Gracijela and Scheja, Agneta and Saxne, Tore},
  issn         = {1462-0332},
  language     = {eng},
  number       = {5},
  pages        = {915--920},
  publisher    = {Oxford University Press},
  series       = {Rheumatology (Oxford, England)},
  title        = {Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease.},
  url          = {http://dx.doi.org/10.1093/rheumatology/ker442},
  volume       = {51},
  year         = {2012},
}